Drugs / EPCAM CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05028933 | Sep 2021 → Dec 2024 | colorectal cancer, gastric cancer, hepatocellular carcinoma, pancreatic neoplasm | Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EpCAM CAR-T | “Pretreatment with fludarabine and cyclophosphamide EpCAM CAR-T Cells infusion” NCT05028933 ↗ |
| Action | Deplete | “clearance effect of CAR-T cell treatment on CTC” NCT05028933 ↗ |
| Modality | Cell therapy | “Autologous T cells modified with chimeric antigen receptor” NCT05028933 ↗ |
| Route | Intravenous | “infused intravenously” NCT05028933 ↗ |
| Target | EPCAM | “chimeric antigen receptor targeting EpCAM” NCT05028933 ↗ |